Note: This document contains side effect information about cetuximab. Some dosage forms listed on this page may not apply to the brand name Erbitux.
Applies to cetuximab: intravenous solution.
Warning
Intravenous route (Solution)
Serious and potentially fatal infusion reactions may occur and require immediate interruption of the cetuximab infusion and permanent discontinuation. Cardiopulmonary arrest and/or sudden death have been reported in patients with squamous cell carcinoma of the head and neck treated with radiation therapy and cetuximab or platinum-based therapy with 5-fluorouracil and cetuximab. Monitoring of serum electrolytes during and after cetuximab therapy is recommended.
Serious side effects of Erbitux
Along with its needed effects, cetuximab (the active ingredient contained in Erbitux) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking cetuximab:
More common
- Blemishes on the skin or pimples
- bloating or swelling of the face, arms, hands, lower legs, or feet
- body aches or pain
- chills
- congestion
- cough
- deep cracks, grooves, or lines in the skin
- difficult or labored breathing
- dizziness
- fever
- headache
- hoarseness
- lower back or side pain
- nausea
- painful or difficult urination
- pale skin
- rapid weight gain
- runny nose
- severe dry skin
- skin rash
- tender, swollen glands in the neck
- tightness in the chest
- tingling of the hands or feet
- trouble with breathing on exertion
- trouble with swallowing
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight gain or loss
- voice changes
- vomiting
Less common
- Anxiety
- black, tarry stools
- chest pain
- confusion
- decreased urination
- dry mouth
- fainting
- fast heartbeat
- increase in heart rate
- lightheadedness
- rapid, shallow breathing
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- sunken eyes
- thirst
- wrinkled skin
Incidence not known
- Blistering, peeling, or loosening of the skin
- cracked lips
- diarrhea
- difficulty in swallowing
- itching
- joint or muscle pain
- red, irritated eyes
- red skin lesions, often with a purple center
- stiff neck or back
Other side effects of Erbitux
Some side effects of cetuximab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Belching
- burning, dry, or itching eyes
- difficulty having a bowel movement
- discharge from the eye
- discoloration of the fingernails or toenails
- discouragement
- excessive tearing
- feeling sad or empty
- hair loss or thinning of the hair
- heartburn
- indigestion
- irritability
- lack or loss of appetite
- lack or loss of strength
- loss of interest or pleasure
- pain
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
- sleeplessness
- stomach discomfort, upset, or pain
- swelling or inflammation of the mouth
- trouble concentrating
- trouble sleeping
For Healthcare Professionals
Applies to cetuximab: intravenous solution.
Dermatologic
Very common (10% or more): Acneiform rash (90%), alopecia (21%), skin fissures (19%), nail disorder (16%), skin disorder (15%), acne (14%)
Common (1% to 10%): Pruritus
Very rare (less than 0.01%): Stevens-Johnson syndrome/toxic necrolysis
Frequency not reported: Superinfection of skin lesions
Postmarketing reports: Life-threatening/fatal bullous mucocutaneous disease[Ref]
Cardiovascular
Common (1% to 10%): Cardiopulmonary arrest and/or sudden death
Uncommon (0.1% to 1%): Deep vein thrombosis[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (66%), nausea (55%), vomiting (41%), anorexia (36%), constipation (30%), stomatitis (26%), dyspepsia (14%), mucositis, dry mouth (12%)
Postmarketing reports: Mucosal inflammation[Ref]
Hematologic
Very common (10% or more): Leukopenia (25%), anemia (16%)[Ref]
Respiratory
Very common (10% or more): Dyspnea (49%), cough (30%)
Uncommon (0.1% to 1%): Pulmonary embolism, interstitial lung disease[Ref]
Metabolic
Very common (10% or more): Hypomagnesemia (55%), sensory neuropathy (45%), weight loss (21%), peripheral edema (16%), dehydration (15%), severe hypomagnesemia (15%)
Common (1% to 10%): Hypocalcemia, anorexia[Ref]
Other
Very common (10% or more): Asthenia (56%), fever (29%), chills (16%), taste disturbance (10%)
Common (1% to 10%): Fatigue
Frequency not reported: Late radiation toxicity[Ref]
Ocular
Very common (10% or more): Conjunctivitis (14%)
Uncommon (0.1% to 1%): Blepharitis, keratitis[Ref]
Nervous system
Very common (10% or more): Headache (19%)
Frequency not reported: Aseptic meningitis[Ref]
Renal
Common (1% to 10%): Kidney failure[Ref]
Hypersensitivity
Very common (10% or more): Mild or moderate infusion related reactions
Common (1% to 10%): Severe infusion related reactions (in some cases fatal)[Ref]
Immunologic
Very common (10% or more): Infection (13%)
Frequency not reported: Immunogenicity[Ref]
Musculoskeletal
Very common (10% or more): Arthralgia (14%), back pain (16%)[Ref]
Hepatic
Very common (10% or more): High alanine transaminase (43%), high aspartate transaminase (38%), high alkaline phosphatase (33%)[Ref]
Psychiatric
Very common (10% or more): Insomnia (27%), confusion (18%), anxiety (14%), depression (14%)[Ref]
Local
Very common (10% or more): Infusion reaction (e.g., chills, rigors, dyspnea, tachycardia, bronchospasm, chest tightness, swelling, urticaria, hypotension, flushing, rash, hypertension, nausea, angioedema, pain, sweating, tremors, shaking, drug fever, or other hypersensitivity reaction) (15%)[Ref]